Table 3.

RIC allogeneic HSCT for CLL.

n	Age years (range)	Prior regimens (range)	Chemo-Refractory (%)	Prior Auto-SCT	Donor (includes mismatch)	TRM	GVHD acute gd 2-4	chronic extensive	Survival	Reference
82	82 (42-72)	4	87%	4	63% related 37% unrelated	25%	55%	49% related 53% unrelated	OS 50% 5 yr PFS 45%	Sorror et al 2008 (34)
77	54 (30-66)	3 (0-8)	33%	10	81% related	18% 12m	34%	58%	OS 72% 2 yr PFS 56%	Dreger et al 2003 (35)
46	53 (35-67)	5 (1-10)	57%	10	33% related 67% unrelated	17%	34%	43%	OS 54% 2 yr PFS 34%	Brown et al 2006 (36)
41	54 (37-67)	3 (1-8)	27%	11	58% related 42% unrelated	5% at 100 d 26%	10% (gd 3-4)	33%* *after DLI	OS 51 2 yr PFS 45%	Delgado et al 2006 (37)
39	57 (34-70)	3 (2-8)	Not stated		90% related 10% unrelated	2% at 100 d	45%	58%	OS 48% 4 yr PFS 44%	Khouri et al 2006 (38)
30	50 (12-63)	3 (0-8)	47%		50% related 50% unrelated	13%	56%	21%	OS 72% 2 yr PFS 67%	Schetelig et al 2003 (39)